# Boundless Bio, Inc.

Boundless Bio, Inc. is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

Boundless Bio (Nasdaq: BOLD) is a clinical-stage precision oncology company founded in 2018 in San Diego, California. The company develops novel therapies for oncogene-amplified cancers through its pipeline of ecDNA-directed therapies (ecDTx). Boundless Bio was formerly known as Pretzel Therapeutics.

## Questions

### What is Boundless Bio's core technology?

Boundless Bio focuses on extrachromosomal DNA (ecDNA), a circular DNA element found in some cancer cells that drives oncogene amplification. Its ecDTx platform develops small-molecule inhibitors to kill ecDNA-dependent tumor cells. The company also created ecDNA Canvas, a diagnostic to identify patients with ecDNA-driven tumors.

### Has Boundless Bio raised venture capital?

Yes, Boundless Bio raised over $300 million in total disclosed funding, including a Series C round in September 2024 led by RA Capital Management and Nextech Invest. Earlier rounds included investors such as Foresite Capital and Omega Funds. The Series C proceeds are intended to advance its lead candidate into clinical trials.

### Who are Boundless Bio's competitors?

Boundless Bio operates in a niche area of oncology with few direct competitors targeting ecDNA. Larger biotechs pursuing similar biology include Flagship Pioneering's Apriori Bio, though that firm focuses on different mechanisms. More broadly, the company competes with other precision oncology drug developers.

### Where is Boundless Bio headquartered?

Boundless Bio is headquartered in San Diego, California, within the Sorrento Mesa life sciences cluster. The firm does not disclose additional office locations.

### How does Boundless Bio plan to commercialize its drugs?

Boundless Bio intends to develop its drugs independently through clinical trials and seek partnerships with larger pharmaceutical companies for later-stage development and commercialization. The company's business model is typical of venture-backed biotechs, relying on data generation to attract partners or potential acquisition interest.

## Related profiles

- [Sports Entertainment Gaming Global Corp](https://altss.com/profile/sports-entertainment-gaming-global-corp)

---

Updated: 2026-05-30T22:57:49.810Z

Canonical page: https://altss.com/profile/boundless-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology